Table 1.

Characteristics of included studies.

First author/year	Country	Total	male ratio	Age Median(range)	Survival type	Cut off value(×109/L)	Cut off selection	Group size	Tumor stage	NOS
Berardi R 2019	USA	311	216(69%)	68(25–86)	PFS,OS	1,270	median	High 179 /low 132	III–IV	7
Chen X 2022	China	94	55 (58.5%)	48(18–76)	PFS,OS	842	median	high 47 /low 47	IIIB–IV	6
Deng C 2019	China	203	89 (43.8%)	59(28–79)	PFS,OS	1,066.935	ROC curve analyses	high 63 /low 140	–	7
Fu F 2021	China	3,984	2,139 (53.7%)	60 (53–66)	PFS,OS	479	R package survminer	high 1,643 /low 2,341	I–III	7
Gao Y 2018	China	410	267(65.12%)	–	OS	395.4	ROC curve analyses	high 270 /low 140	T1–T4	7
Guo D 2018	China	140	95 (67.9%)	62(33–83)	PFS,OS	521	ROC curve analyses	high 72 /low 68	IIIB – IV	7
Guo W	China	569	425 (74.7%)	60(27–80)	OS	419.6	ROC curve analyses	high 307 /low 262	I–III	7
Hong X 2015	China	919	635 (69.1%)	56(16–84)	OS	1,600	ROC curve analyses	high 127 /low 792	I–IV	7
Ju Q 2021	China	102	41 (40.2%)	59.50(30–80)	PFS,OS	841.03	ROC curve analyses	NA	III–IV	6
Keit E 2021	USA	125	64 (51.2%)	67(45–86)	PFS,OS	1,266	ROC curve analyses	high 55 /low 70	III	7
Li A 2020	China	252	145(57.5%)	58 (24–84)	OS	630.85	ROC curve analyses	high 154 /low 98	Brain metastasis	7
Li X 2020	China	345	255(73.9%)	64 (25–93)	OS	555.59	ROC curve analyses	high 196 /low 149	IIIB – IV	7
Takeda T 2021	Japan	42	22(52.4%)	67(29–85)	PFS	1,000	ROC curve analyses	high 15 /low 27	I–III	7
Tong YS 2017	China	332	206 (62%)	61(34–70)	OS	660	ROC curve analyses	high 149 /low 183	IIIA – IIIB	7
Watanabe K 2021	Japan	387	233(60.2%)	71(19–86)	RFS	715	ROC curve analyses	high 97 /low 290	IA–IIA	7
Yan X 2020	China	538	343 (63.8%)	60 (24–82)	DFS,OS	402.37	ROC curve analyses	high 339 /low 199	I–IIIA	7
Zhang Y 2021	China	124	56(45.2%)	60 (38–73)	PFS,OS	480	ROC curve analyses	high 66 /low 58	I–III	7